Tags

Type your tag names separated by a space and hit enter

Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
Am J Obstet Gynecol. 2001 Nov; 185(5):1180-5.AJ

Abstract

OBJECTIVE

The purpose of this study was to determine the effects of a low dose of conjugated equine estrogens and medroxyprogesterone acetate plus calcium supplementation on bone density, metabolism, body weight, and symptoms in young postmenopausal women.

STUDY DESIGN

Sixty postmenopausal women, aged 45 to 56 years, were randomized in an open-label, 2-year trial that compared treatment with low-dose continuous combined hormone replacement therapy that contained 0.3 mg of conjugated equine estrogens and 2.5 mg of medroxyprogesterone acetate plus 1000 mg of calcium per day or treatment with 1000 mg of calcium per day alone. Menopausal symptoms were evaluated for the first 12 weeks of the study; bleeding profiles, bone mineral density, bone turnover, and body weight were assessed for 24 months.

RESULTS

After 24 months, we evaluated 15 subjects in the control group (with a 50% drop-out rate) and 23 patients (with a 23% drop-out rate) in the low-dose continuous combined hormone replacement therapy group. Low-dose continuous combined hormone replacement therapy was effective in reducing menopausal clinical symptoms and provided a favorable bleeding profile and minimal side effects. In comparison with basal values, bone mineral density significantly (P <.05) increased by 2.72% +/- 0.3% in the low-dose continuous combined hormone replacement therapy group and decreased by 7.9% +/- 0.8% (P <.05) in the control group after 24 months, with parallel changes in bone metabolism marker action. In the control group, body mass index significantly (P <.05) increased from baseline value with a weight gain of 3%; in the low-dose continuous combined hormone replacement therapy group, the body mass index did not change after 24 months of treatment, and the 1.3% gain in body weight was not significant.

CONCLUSION

Low-dose continuous combined hormone replacement therapy can alleviate subjective symptoms and minimize body transformations that are associated with early menopause and provide an effective protection against the activation of bone turnover and osteoporosis.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University of Pisa, Italy. margamba@tin.itNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

11717654

Citation

Gambacciani, M, et al. "Effects of Low-dose Continuous Combined Conjugated Estrogens and Medroxyprogesterone Acetate On Menopausal Symptoms, Body Weight, Bone Density, and Metabolism in Postmenopausal Women." American Journal of Obstetrics and Gynecology, vol. 185, no. 5, 2001, pp. 1180-5.
Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol. 2001;185(5):1180-5.
Gambacciani, M., Ciaponi, M., Cappagli, B., & Genazzani, A. R. (2001). Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. American Journal of Obstetrics and Gynecology, 185(5), 1180-5.
Gambacciani M, et al. Effects of Low-dose Continuous Combined Conjugated Estrogens and Medroxyprogesterone Acetate On Menopausal Symptoms, Body Weight, Bone Density, and Metabolism in Postmenopausal Women. Am J Obstet Gynecol. 2001;185(5):1180-5. PubMed PMID: 11717654.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. AU - Gambacciani,M, AU - Ciaponi,M, AU - Cappagli,B, AU - Genazzani,A R, PY - 2001/11/22/pubmed PY - 2002/1/5/medline PY - 2001/11/22/entrez SP - 1180 EP - 5 JF - American journal of obstetrics and gynecology JO - Am J Obstet Gynecol VL - 185 IS - 5 N2 - OBJECTIVE: The purpose of this study was to determine the effects of a low dose of conjugated equine estrogens and medroxyprogesterone acetate plus calcium supplementation on bone density, metabolism, body weight, and symptoms in young postmenopausal women. STUDY DESIGN: Sixty postmenopausal women, aged 45 to 56 years, were randomized in an open-label, 2-year trial that compared treatment with low-dose continuous combined hormone replacement therapy that contained 0.3 mg of conjugated equine estrogens and 2.5 mg of medroxyprogesterone acetate plus 1000 mg of calcium per day or treatment with 1000 mg of calcium per day alone. Menopausal symptoms were evaluated for the first 12 weeks of the study; bleeding profiles, bone mineral density, bone turnover, and body weight were assessed for 24 months. RESULTS: After 24 months, we evaluated 15 subjects in the control group (with a 50% drop-out rate) and 23 patients (with a 23% drop-out rate) in the low-dose continuous combined hormone replacement therapy group. Low-dose continuous combined hormone replacement therapy was effective in reducing menopausal clinical symptoms and provided a favorable bleeding profile and minimal side effects. In comparison with basal values, bone mineral density significantly (P <.05) increased by 2.72% +/- 0.3% in the low-dose continuous combined hormone replacement therapy group and decreased by 7.9% +/- 0.8% (P <.05) in the control group after 24 months, with parallel changes in bone metabolism marker action. In the control group, body mass index significantly (P <.05) increased from baseline value with a weight gain of 3%; in the low-dose continuous combined hormone replacement therapy group, the body mass index did not change after 24 months of treatment, and the 1.3% gain in body weight was not significant. CONCLUSION: Low-dose continuous combined hormone replacement therapy can alleviate subjective symptoms and minimize body transformations that are associated with early menopause and provide an effective protection against the activation of bone turnover and osteoporosis. SN - 0002-9378 UR - https://www.unboundmedicine.com/medline/citation/11717654/Effects_of_low_dose_continuous_combined_conjugated_estrogens_and_medroxyprogesterone_acetate_on_menopausal_symptoms_body_weight_bone_density_and_metabolism_in_postmenopausal_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9378(01)67550-1 DB - PRIME DP - Unbound Medicine ER -